The effectiveness of the hair-restorer “DABAO” in males with alopecia androgenetica. a clinical experiment

Kessels, Alphons G.H.; Cardynaals, R.L.L.M.; Borger, Rebecca; Go, Martin J.; Lambers, J.C.C.A.; Knottnerus, J.A.; Knipschild, Paul

doi:10.1016/0895-4356(91)90083-l

Cited by 25 publications

(16 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to lack of placebo respectively standard for comparison the results are deficient. Two trials examining the efficacy of topical applied herbal preparations fulfilled the inclusion criteria of the guideline [93, 94]. As the ingredients of the particular herbal preparations significantly differ, they have to be evaluated separately.…”

Section: Therapeutic Options and Therapy Assessmentmentioning

confidence: 99%

“…Kessels et al reported modest increase in hair regrowth in 396 male patients, who applied a Chinese herbal preparation twice daily for 6 months. The mean change in nonvellus hair counts was 26.6 hairs/cm 2 vs. 21.8 hairs/cm 2 , p = 0.02 vs. placebo) [94]. Greenberg et al reported a mean change from baseline total hair count of 77.4 % in 24 men after 40 weeks usage of herbal extract containing fennel, poly‐gonum, menthe, chamomile, thuja, hibiscus) (p = 0.003) [93].…”

Section: Therapeutic Options and Therapy Assessmentmentioning

confidence: 99%

See 1 more Smart Citation

Evidence‐based (S3) guideline for the treatment of androgenetic alopecia in women and in men

Blumeyer

Tosti

Messenger

et al. 2011

J Deutsche Derma Gesell

246

223

View full text Add to dashboard Cite

SummaryAndrogenetic alopecia is the most common hair loss disorder, affecting both men and women. Initial signs of androgenetic alopecia usually develop during teenage years leading to progressive hair loss with a pattern distribution. Moreover, its frequency increases with age and affects up to 80 % Caucasian men and 42 % of women. Patients diagnosed with androgenetic alopecia may undergo significant impairment of quality of life. Despite the high prevalence and the variety of therapeutic options available, there have been no national or international evidencebased guidelines for the treatment of androgenetic alopecia in men and women so far. Therefore, the European Dermatology Forum (EDF) initiated a project to develop an evidence-based S3 guideline for the treatment of androgenetic alopecia. Based on a systematic literature research the efficacy of the currently available therapeutic options was assessed and therapeutic recommendations were passed in a consensus conference. The purpose of the guideline is to provide dermatologists as well as general practitioners with an evidence-based tool for choosing an efficacious and safe therapy for patients with androgenetic alopecia. Keywords• alopecia • androgenetic • Therapy • Guideline • hair loss I Introduction to the guideline Needs/problems and issues in patient careAndrogenetic alopecia (AGA) is a common chronic dermatologic disease, affecting both men and women. It is characterized by progressive hair loss usually occurring in a pattern distribution. The frequency increases with age. In Caucasians, at the age of 70 or beyond 80 % of men and up to 42 % of women have signs of androgenetic alopecia. Though the prevalence is high in elderly patients, androgenetic alopecia often already starts at puberty.Independent of age and gender, patients diagnosed with androgenetic alopecia undergo significant impairment in their quality of life. Hair is an important feature of image. Hair loss affects self-esteem, personal attractiveness and may lead to depression and other negative effects of life [1]. Androgenetic alopecia is clearly a burden for both sexes, but it is substantially more distressing for women [2].

show abstract

Section: Therapeutic Options and Therapy Assessmentmentioning

confidence: 99%

Section: Therapeutic Options and Therapy Assessmentmentioning

confidence: 99%

Evidence‐based (S3) guideline for the treatment of androgenetic alopecia in women and in men

Blumeyer

Tosti

Messenger

et al. 2011

J Deutsche Derma Gesell

246

223

View full text Add to dashboard Cite

show abstract

“…67 In this study, 396 patients participated in the doubleblind placebo trial, which lasted 6 months. The components of Dabao include 50% ethanol, 42% water, and 8% Chinese herbal extracts, including saffron flowers, mulberry leaves, stemona root, fruits of the pepper plant, sesame leaves, the skin of the Szechuan pepper fruit, ginger root, Chinese angelica root, bark of the pseudolarix, and fruit of the hawthorn.…”

Section: Chinese Herbal Medicinementioning

confidence: 99%

Herbal Therapy in Dermatology

Bedi

Shenefelt²

2002

Arch Dermatol

192

137

View full text Add to dashboard Cite

“…Sixteen studies met inclusion criteria ( Figure 1) [8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23] . A total of 1,709 male participants were included with an average age of 40 years.…”

Section: Results Of Literature Searchmentioning

confidence: 99%

“…A total of 1,709 male participants were included with an average age of 40 years. Fourteen off-label topical therapies were investigated: a penta-peptide (Gly-Pro-Iie-Gly-Ser), adenosine, bimatoprost, Curcuma aeruginosa extract, dabao, fulvestrant, a herbal extract, latanoprost, a non-steroidal anabolic hormone gel, procyanidin oligomers, pyrithione zinc, roxithromycin, sodium valproate and viprostol (Tables 1-3) [8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23] . Treatment duration ranged from 4 weeks 23 to 52 weeks 21 with 24 weeks the most common duration (10/16 = 63%) 9,12,[15][16][17][18][19][21][22][23] .…”

Section: Results Of Literature Searchmentioning

confidence: 99%

Efficacy of Off-Label Topical Treatments for the Management of Androgenetic Alopecia: A Review

et al. 2019

View full text Add to dashboard Cite

Androgenetic alopecia (AGA) is characterized by non-scarring follicle miniaturization. Despite the success of approved therapies, commonly reported side effects and the need for continual use has led to the investigation of alternative therapies. The aim of this paper is to critically review the success of off-label, topical monotherapies for treatment of AGA in men. A literature search was conducted to obtain randomized, controlled and blinded studies that investigated off-label, topical, monotherapies in male patients. Hair density, hair diameter and hair growth were used to evaluate treatment success. Fourteen off-label topical therapies were investigated among the 16 studies that met inclusion criteria. Nine off-label therapies were reported to produce a significantly greater improvement in hair restoration parameters (e.g., mean change from hair count and hair diameter) as compared to placebo (p<0.05 for all treatments). In two studies, procyanidin oligomers exhibited greater efficacy over vehicle with response to mean change in hair density (hairs/cm 2) (p s < 0.0001 at week 24). In conclusion, prostaglandin analogs and polyphenols, such as latanoprost and procyanidin oligomers, can improve hair restoration parameters in male AGA patients, possibly through targeting mechanisms proposed in the etiology of AGA. The current evidence suggests short term (24 weeks) use may provide benefit for hair loss patients; however, long-term efficacy and safety data are required.

show abstract

The effectiveness of the hair-restorer “DABAO” in males with alopecia androgenetica. a clinical experiment

Cited by 25 publications

References 11 publications

Evidence‐based (S3) guideline for the treatment of androgenetic alopecia in women and in men

Evidence‐based (S3) guideline for the treatment of androgenetic alopecia in women and in men

Herbal Therapy in Dermatology

Efficacy of Off-Label Topical Treatments for the Management of Androgenetic Alopecia: A Review

Contact Info

Product

Resources

About